Risk management profile of etoricoxib: An example of personalized medicine

Therapeutics and Clinical Risk Management

Volumn 4, Issue 5, 2008, Pages 983-997

  Patrignani, Paola ^a   Tacconelli, Stefania ^a   Capone, Marta L ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Cardiovascular toxicity; COX 2; Etoricoxib; Gastrointestinal toxicity; Nonsteroidal antiinflammatory drugs; Prostacyclin

Indexed keywords

ACETYLSALICYLIC ACID; ALGIX; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; ENDOTOXIN; ETORICOXIB; IBUPROFEN; PROSTANOID; PROTON PUMP INHIBITOR; TAUXIB; UNCLASSIFIED DRUG;

ANTINOCICEPTION; CARDIOTOXICITY; CARDIOVASCULAR RISK; CHRONIC DRUG ADMINISTRATION; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG WITHDRAWAL; DYSPEPSIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; GASTROINTESTINAL TOXICITY; GENE ACTIVITY; GENE EXPRESSION REGULATION; HUMAN; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; PEPTIC ULCER BLEEDING; REVIEW; RISK MANAGEMENT; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOSIS;

EID: 56749087774     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Agrawal NG, Porras AG, Matthews CZ, et al. 2003. Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man. J Clin Pharmacol, 43:268-76.
2. Alfranca A, Iñiguez MA, Fresno M, et al. 2006. Prostanoid signal transduction and gene expression in the endothelium: role in cardiovascular diseases. Cardiovasc Res, 70:446-56.
3. Antman EM, Bennett JS, Daugherty A, et al. 2007. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation, 115:1634-42.
4. Arehart E, Stitham J, Asselbergs FW, et al. 2008. Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. Circ Res, 102:986-93.
5. Arnett FC, Edworthy SM, Bloch DA, et al. 1988. The American rheumatism association 1987 revised criteria for the classification of rheumatiod arthritis. Arthritis Rheum, 31:315-24.
6. Asano K, Lilly CM, Drazen JM. 1996. Prostaglandin G/H synthase-2 is the constitutive and dominant isoform in cultured human lung epithelial cells. Am J Physiol Lung Cell Mol Physiol, 271:L126-31.
7. Beiche F, Scheuerer S, Brune K, et al. 1996. Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett, 390:165-9.
8. Bingham CO 3rd, Sebba AI, Rubin BR, et al. 2007. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford), 46:496-507.
9. Bresalier RS, Sandler RS, Quan H, et al. 2005. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med, 352:1092-102.
10. Breyer RM, Bagdassarian CK, Myers SA, et al. 2001. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol, 41:661-90.
11. Burke A, Smyth E, FitzGerald GA. 2006. Analgesic-antipyretic agents; Pharmacotherapy of gout. In: Brunton LL, Lazo JS, Parker KL. (ed) Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, USA, McGRAW-HILL, Medical Publishing Division. p673-715.
12. Cannon CP, Curtis SP, FitzGerald GA, et al. 2006. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet, 368:1771-81.
13. Capone ML, Tacconelli S, Francesco LD, et al. 2008. Cardiovascular effects of valdecoxib: transducing human pharmacology results into clinical read-outs. Expert Opin Drug Saf, 7:29-42.
14. Capone ML, Tacconelli S, Di Francesco L, et al. 2007. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat, 82:85-94.
15. Capone ML, Tacconelli S, Sciulli MG, et al. 2004. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation, 109:1468-71.
16. Carlson ML, Wilson ET, Prescott SM. 2003. Regulation of COX-2 transcription in a colon cancer cell line by Pontin52/TIP49a. Mol Cancer, 2:42.
17. Catella-Lawson F, McAdam B, Morrison BW, et al. 1999. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther, 289:735-41.
18. Cryer B, Feldman M. 1998. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med, 104:413-21.
19. Egan KM, Lawson JA, Fries S, et al. 2004. COX-2-derived prostacyclin confers atheroprotection on female mice. Science, 306:1954-7.
20. Fitzgerald GA, Patrono C. 2001. The Coxibs, selective inhibitors of Cyclooxygenase-2. N Engl J Med, 345:433-42.
21. FitzGerald GA. 2003. COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov, 2:879-90.
22. Funk CD. 2001. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science, 294:1871-5.
23. Grosser T, Fries S, FitzGerald GA. 2006. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest, 116:4-15.
24. Harris RC, McKanna JA, Akai Y, et al. 1994. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. Clin Invest, 94:2504-10.
25. Hernández-Díaz S, Varas-Lorenzo C, García Rodríguez LA. 2006. Nonsteroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol, 98:266-74.
26. Huntjens DR, Danhof M, Della Pasqua OE. 2005. Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. Rheumatology (Oxford), 44:846-59.
27. Inoue A, Ikoma K, Morioka N, et al. 1999. Interleukin-1beta induces substance P release from primary afferent neurons through the cyclooxygenase-2 system. J Neurochem, 73:2206-13.
28. Kang YJ, Mbonye UR, DeLong CJ, et al. 2007. Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradation. Prog Lipid Res, 46:108-25.
29. Kargman S, Charleson S, Cartwright M, et al. 1996. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology, 111:445-54.
30. Kassahun K, McIntosh IS, Shou M, et al. 2001. Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Metab Dispos, 29:813-20.
31. Kaufmann WE, Worley PF, Taylor CV, et al. 1997. Cyclooxygenase-2 expression during rat neocortical development and in Rett syndrome. Brain Dev, 19:25-34.
32. Kearney PM, Baigent C, Godwin J, et al. 2006. Do selective cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ, 332:1302-8.
33. Konturek SJ, Konturek PC, Brzozowski T. 2005. Prostaglandins and ulcer healing. J Physiol Pharmacol, 56:5-31.
34. Kulmacz RJ, Wang LH. 1995. Comparison of hydroperoxide initiator requirements for the cyclooxygenase activities of prostaglandin H synthase-1 and -2. J Biol Chem, 270:24019-23.
35. Laine L, Curtis SP, Cryer B, et al. 2007. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomized comparison. Lancet, 369:465-73.
36. Leung AT, Malmstrom K, Gallacher AE, et al. 2002. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: a randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin, 18:49-58.
37. Malkowski MG, Ginell SL, Smith WL, et al. 2000. The productive conformation of arachidonic acid bound to prostaglandin synthase. Science, 289:1933-7.
38. Marnett LJ, Rowlinson SW, Goodwin DC, et al. 1999. Arachidonic acid oxygenation by COX-1 and COX-2: mechanisms of catalysis and inhibition. J Biol Chem, 274:22903-6.
39. McAdam BF, Catella-Lawson F, Mardini IA, et al. 1999. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A, 96:272-7.
40. Minuz P, Fumagalli L, Gaino S, et al. 2006. Rapid stimulation of tyrosine phosphorylation signals downstream of G-protein-coupled receptors for thromboxane A2 in human platelets. Biochem J, 400:127-34.
41. Minuz P, Gaino S, Zuliani V, et al. 2002. Functional role of p38 mitogen activated protein kinase in platelet activation induced by a thromboxane A2 analogue and by 8-iso-prostaglandin F2alpha. Thromb Haemost, 87:888-98.
42. Moncada S, Higgs EA, Vane JR. 1977. Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet, 1:18-20.
43. Murata T, Ushikubi F, Matsuoka T, et al. 1997. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature, 388:678-82.
44. Nakao K, Murase A, Ohshiro H, et al. 2007. CJ-023,423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties. J Pharmacol Exp Ther, 322:686-94.
45. Nardone G, Rocco A, Vaira D, et al. 2004. Expression of COX-2, mPGE-synthase1, MDR-1 (P-gp), and Bcl-xL: a molecular pathway of H pylori-related gastric carcinogenesis. J Pathol, 202:305-12.
46. Narumiya S, Sugimoto Y, Ushikubi F. 1999. Prostanoid receptors: structures, properties, and functions. Physiol Rev, 79:1193-226.
47. Nussmeier NA, Whelton AA, Brown MT, et al. 2005. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med, 352:1081-91.
48. Ott E, Nussmeier NA, Duke PC, et al. 2003. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg, 125:1481-92.
49. Patrignani P, Capone ML, Tacconelli S. 2008c. NSAIDs and cardiovascular disease. Heart, 94:395-7.
50. Patrignani P, Campestrini J, Branson J, et al. 2004. Lumiracoxib is a selective inhibitor of cyclooxygenase-2 in patients with osteoarthritis. Ann Rheum Dis, 63: 368.
51. Patrignani P, Di Febbo C, Tacconelli S, et al. 2008b. Differential association between human prostacyclin receptor polymorphisms and the development of venous thrombosis and intimal hyperplasia: a clinical biomarker study. Pharmacogenetics and Genomics, 18:611-20.
52. Patrignani P, Panara MR, Greco A, et al. 1994. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther, 271:1705-12.
53. Patrignani P, Panara MR, Sciulli MG, et al. 1997. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Physiol Pharmacol, 48:623-31.
54. Patrignani P, Sciulli MG, Manarini S, et al. 1999. COX-2 is not involved in thromboxane biosynthesis by activated human platelets. J Physiol Pharmacol, 50:661-7.
55. Patrignani P, Tacconelli S, García Rodríguez LA. 2008a. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. Arterioscler Thromb Vasc Biol, 28:e-45.
56. Patrono C, Ciabattoni G, Pinca E, et al. 1980. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res, 17:317-27.
57. Patrono C, Patrignani P, García Rodríguez LA. 2001. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest, 108:7-13.
58. Pfizer. A double-blind randomised placebo-controlled comparative study of celecoxib (SC-58635) for the inhibition of progression of Alzheimer's disease, protocol IQ5-97-02-001.2000 [online]. Accessed 21 November 2005. URL: http://www.clinicalstudyresults.org/documents/ company-study_76_0.pdf
59. Prescott SM, Fitzpatrick FA. 2000. Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta, 1470:M69-78.
60. Pulcinelli FM, Riondino S, Celestini A, et al. 2005. Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin. J Thromb Haemost, 3:2784-9.
61. Qi Z, Hao C-M, Langenbach RI, et al. 2002. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest, 110:61-9.
62. Ramwell PW, Foegh M, Loeb R, et al. 1980. Synthesis and metabolism of prostaglandins, prostacyclin, and thromboxanes: the arachidonic acid cascade. Semin Perinatol, 4:3-13.
63. Reilly IA, FitzGerald GA. 1987. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood, 69:180-6.
64. Riendeau D, Percival MD, Brideau C, et al. 2001. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther, 296:558-66.
65. Ristimaki A, Honkanen N, Jankala H, et al. 1997. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res, 57:1276-80.
66. Roberts LJ II. 1987. Handbook of eicosanoids: prostaglandins and related lipids. Boca Raton, FL: CRC p. 233-44.
67. Robertson RP. 1998. Dominance of cyclooxygenase-2 in the regulation of pancreatic islet prostaglandin synthesis. Diabetes, 47:1379-83.
68. Rocca B, Spain LM, Pure E, et al. 1999. Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. J Clin Invest, 103:1469-77.
69. Romano M, Ricci V, Memoli A, et al. 1998. Helicobacter pylori up-regulates cyclooxygenase-2 mRNA expression and prostaglandin E2 synthesis in MKN 28 gastric mucosal cells in vitro. J Biol Chem, 273:28560-3.
70. Samad TA, Moore KA, Sapirstein A, et al. 2001. Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature, 410:471-5.
71. Sciulli MG, Capone ML, Tacconelli S, et al. 2005. The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain. Pharmacol Rep, 57:66-85.
72. Sciulli MG, Renda G, Capone ML, et al. 2006. Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease. Clin Pharmacol Ther, 80:115-25.
73. Shao J, Sheng H, Inoue H, et al. 2000. Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J Biol Chem, 275:33951-6.
74. Shigeta J, Takahashi S, Okabe S. 1998. Role of cyclooxygenase-2 in the healing of gastric ulcers in rats. J Pharmacol Exp Ther, 286:1383-90.
75. Simmons DL, Botting RM, Hla T. 2004. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev, 56:387-437.
76. Smith W, DeWitt D, Garavito R. 2000. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem, 69:145-82.
77. Solomon SD, McMurray JJ, Pfeffer MA, et al. 2005. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med, 352:1071-80.
78. Solomon SD, Wittes J, Finn PV, et al. 2008. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials. The Cross Trial Safety Analysis. Circulation, 117:2104-13.
79. Swinney DC, Mak AY, Barnett J, et al. 1997. Differential allosteric regulation of prostaglandin H synthase 1 and 2 by arachidonic acid. J Biol Chem, 272:12393-8.
80. Tacconelli S, Capone ML, Sciulli MG, et al. 2002. The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. Curr Med Res Opin, 18:503-11.
81. Takahashi S, Shigeta J, Inoue H, et al. 1998. Localization of cyclooxygenase-2 and regulation of its mRNA expression in gastric ulcers in rats. Am J Physiol, 275:G1137-45.
82. Tonai T, Taketani Y, Ueda N, et al. 1999. Possible involvement of interleukin-1 in cyclooxygenase-2 induction after spinal cord injury in rats. J Neurochem, 72:302-9.
83. Vane JR, Bakhle YS, Botting RM. 1998. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol, 38:97-120.
84. Wang D, Dubois RN. 2006. Prostaglandins and cancer. Gut, 55:115-22.
85. Wiesenhutter CW, Boice JA, Ko A, et al. 2005. Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc, 80:470-9.
86. Wilson DE. 1991. Role of prostaglandins in gastroduodenal mucosal protection. J Clin Gastroenterol, 13:S65-71.
87. Yamagata K, Andreasson KI, Kaufmann WE, et al. 1993. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron, 11:371-86.
88. Yu Y, Fan J, Hui Y, et al. 2007. Targeted cyclooxygenase gene (ptgs) exchange reveals discriminant isoform functionality. J Biol Chem, 282:1498-506.